The idea is to maintain the metabolic benefits of tirzepatide while minimizing long-term exposure and side effects
Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or quality
Key trial programs include SURMOUNT (tirzepatide for weight management, NEJM 2022), SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024), and STEP (semaglutide, NEJM 2021)
Mounjaro Mounjaro (tirzepatide) is known as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
23110 W Interstate 10 Frontage Rd
We complement these IV treatments with acupuncture, naturopathic medicine, and other holistic treatments